BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

Compare

2,362 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BMRN Analyst Ratings

Moderate Buy

14 Buy

5 Hold

0 Sell

Based on 19 analysts giving stock ratings to

BioMarin

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BMRN Stock 12 Month Forecast

Average Price Target

$87.44

▲(68.80% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $87.44 with a high forecast of $120.00 and a low forecast of $55.00. The average price target represents a 68.80% change from the last price of $51.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"$52","121":"$121","69.25":"$69.3","86.5":"$86.5","103.75":"$103.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$87.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,69.25,86.5,103.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.03,60.027692307692305,65.02538461538461,70.02307692307693,75.02076923076923,80.01846153846154,85.01615384615386,90.01384615384616,95.01153846153846,100.00923076923077,105.00692307692307,110.00461538461539,115.0023076923077,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.03,57.52307692307692,60.01615384615385,62.50923076923077,65.0023076923077,67.49538461538461,69.98846153846154,72.48153846153846,74.97461538461539,77.4676923076923,79.96076923076923,82.45384615384614,84.94692307692307,{"y":87.44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.03,55.027692307692305,55.02538461538462,55.02307692307692,55.02076923076923,55.01846153846154,55.01615384615385,55.01384615384615,55.011538461538464,55.00923076923077,55.00692307692308,55.004615384615384,55.002307692307696,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.94,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.09,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$87.44

Lowest Price Target$55.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Paul Matteis

Stifel Nicolaus

―

Hold

―

Reiterated

12/11/25

Stifel Nicolaus Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)

Joseph Schwartz

Leerink Partners

$60

Hold

15.83%

Upside

Downgraded

12/03/25

BioMarin downgraded to Market Perform from Outperform at LeerinkBioMarin downgraded to Market Perform from Outperform at Leerink

William Pickering

Bernstein

$95→$88

Buy

69.88%

Upside

Assigned

10/31/25

BioMarin price target lowered to $88 from $95 at BernsteinBioMarin price target lowered to $88 from $95 at Bernstein

Joon Lee

Truist Financial

$90→$80

Buy

54.44%

Upside

Reiterated

10/28/25

BioMarin Pharmaceutical (BMRN) Receives a Rating Update from a Top AnalystLowering PT from $90 to $80 on lowered Voxzogo outlook but maintain Buy on key upcoming catalysts.

Cory Kasimov

Evercore ISI

$110

Buy

112.36%

Upside

Reiterated

10/28/25

Evercore ISI Remains a Buy on BioMarin Pharmaceutical (BMRN)

Akash Tewari

Jefferies

$113

Buy

118.15%

Upside

Reiterated

10/28/25

Jefferies Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Mohit Bansal

Wells Fargo

$90→$70

Buy

35.14%

Upside

Reiterated

10/28/25

BioMarin price target lowered to $70 from $90 at Wells FargoBioMarin price target lowered to $70 from $90 at Wells Fargo

Sean Laaman

Morgan Stanley

$104→$98

Buy

89.19%

Upside

Reiterated

10/28/25

BioMarin Pharmaceutical: Strong Growth Potential Amidst Competitive Challenges

Sami Corwin

William Blair

―

Hold

―

Reiterated

10/28/25

William Blair Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)We summarize BioMarin’s financial results compared to our estimates and consensus in exhibit 1 of the full report and our model updates in exhibit 2. Lower bound of 2025 revenue guidance raised, but non-GAAP EPS guidance lowered: The company raised the lower bound of its 2025 revenue guidance from 3.125 billion to 3.150 billion (upper bound remains $3.2 billion) and reaffirmed Voxzogo guidance of $900 million-$935 million. On the call, management cited the $221 million pre-tax acquired in-process research and development (IPR&D) charge associated with the acquisition of Inozyme as the driver of its change in profitability guidance, with non-GAAP operating margin guidance cut from 33%-34% to 26%-27% and non-GAAP diluted EPS from $4.40-$4.55 to $3.50-$3.60.

Leland Gershell

Oppenheimer

$98

Buy

89.19%

Upside

Reiterated

10/28/25

BioMarin Pharmaceutical (BMRN) Gets a Buy from Oppenheimer

Christopher Raymond

Raymond James

$85

Buy

64.09%

Upside

Reiterated

10/28/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Revvity (NYSE: RVTY)

Gena Wang

Barclays

$86→$80

Buy

54.44%

Upside

Reiterated

10/28/25

Barclays Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Mitchell Kapoor

H.C. Wainwright

$60→$55

Hold

6.18%

Upside

Reiterated

10/28/25

BioMarin price target lowered to $55 from $60 at H.C. WainwrightBioMarin price target lowered to $55 from $60 at H.C. Wainwright

Yun Zhong

Wedbush

$94

Buy

81.47%

Upside

Reiterated

10/28/25

BioMarin Pharmaceutical: Strong Growth Prospects and Strategic Initiatives Justify Buy RatingReiterate OUTPERFORM rating and $94PT on BMRNshares while we wait for competitive dynamics to play out in 2026.

Jason Gerberry

Bank of America Securities

$103→$102

Buy

96.91%

Upside

Reiterated

10/27/25

Bank of America Securities Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Paul Matteis

Stifel Nicolaus

―

Hold

―

Reiterated

12/11/25

Stifel Nicolaus Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)

Joseph Schwartz

Leerink Partners

$60

Hold

15.83%

Upside

Downgraded

12/03/25

BioMarin downgraded to Market Perform from Outperform at LeerinkBioMarin downgraded to Market Perform from Outperform at Leerink

William Pickering

Bernstein

$95→$88

Buy

69.88%

Upside

Assigned

10/31/25

BioMarin price target lowered to $88 from $95 at BernsteinBioMarin price target lowered to $88 from $95 at Bernstein

Joon Lee

Truist Financial

$90→$80

Buy

54.44%

Upside

Reiterated

10/28/25

BioMarin Pharmaceutical (BMRN) Receives a Rating Update from a Top AnalystLowering PT from $90 to $80 on lowered Voxzogo outlook but maintain Buy on key upcoming catalysts.

Cory Kasimov

Evercore ISI

$110

Buy

112.36%

Upside

Reiterated

10/28/25

Evercore ISI Remains a Buy on BioMarin Pharmaceutical (BMRN)

Akash Tewari

Jefferies

$113

Buy

118.15%

Upside

Reiterated

10/28/25

Jefferies Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Mohit Bansal

Wells Fargo

$90→$70

Buy

35.14%

Upside

Reiterated

10/28/25

BioMarin price target lowered to $70 from $90 at Wells FargoBioMarin price target lowered to $70 from $90 at Wells Fargo

Sean Laaman

Morgan Stanley

$104→$98

Buy

89.19%

Upside

Reiterated

10/28/25

BioMarin Pharmaceutical: Strong Growth Potential Amidst Competitive Challenges

Sami Corwin

William Blair

―

Hold

―

Reiterated

10/28/25

Leland Gershell

Oppenheimer

$98

Buy

89.19%

Upside

Reiterated

10/28/25

BioMarin Pharmaceutical (BMRN) Gets a Buy from Oppenheimer

Christopher Raymond

Raymond James

$85

Buy

64.09%

Upside

Reiterated

10/28/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Revvity (NYSE: RVTY)

Gena Wang

Barclays

$86→$80

Buy

54.44%

Upside

Reiterated

10/28/25

Barclays Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Mitchell Kapoor

H.C. Wainwright

$60→$55

Hold

6.18%

Upside

Reiterated

10/28/25

BioMarin price target lowered to $55 from $60 at H.C. WainwrightBioMarin price target lowered to $55 from $60 at H.C. Wainwright

Yun Zhong

Wedbush

$94

Buy

81.47%

Upside

Reiterated

10/28/25

Jason Gerberry

Bank of America Securities

$103→$102

Buy

96.91%

Upside

Reiterated

10/27/25

Bank of America Securities Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

1 Month

xxx

Success Rate

9/15 ratings generated profit

Average Return

-0.85%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of -0.85% per trade.

3 Months

xxx

Success Rate

14/36 ratings generated profit

Average Return

-0.71%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 38.89% of your transactions generating a profit, with an average return of -0.71% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

20/44 ratings generated profit

Average Return

-4.24%

reiterated a buy rating 2 months ago

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -4.24% per trade.

2 Years

xxx

Success Rate

15/44 ratings generated profit

Average Return

-4.81%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 34.09% of your transactions generating a profit, with an average return of -4.81% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMRN Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BMRN has received 22 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the past 3 months is 87.44.

Each month's total comprises the sum of three months' worth of ratings.

BMRN Financial Forecast

BMRN Earnings Forecast

Next quarter’s earnings estimate for BMRN is $0.81 with a range of $0.51 to $1.23. The previous quarter’s EPS was -$0.16. BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Sales Forecast

Next quarter’s sales forecast for BMRN is $824.71M with a range of $810.00M to $852.00M. The previous quarter’s sales results were $786.77M. BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Stock Forecast FAQ

What is BMRN’s average 12-month price target, according to analysts?

Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 87.44.

What is BMRN’s upside potential, based on the analysts’ average price target?

BioMarin Pharmaceutical has 68.80% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BMRN a Buy, Sell or Hold?

BioMarin Pharmaceutical has a consensus rating of Moderate Buy which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings.

What is BioMarin Pharmaceutical’s price target?

The average price target for BioMarin Pharmaceutical is 87.44. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $55.00. The average price target represents 68.80% Increase from the current price of $51.8.

What do analysts say about BioMarin Pharmaceutical?

BioMarin Pharmaceutical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of BMRN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BMRN Analyst Ratings

BMRN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioMarin Pharmaceutical

BMRN Analyst Recommendation Trends

BMRN Financial Forecast

BMRN Earnings Forecast

BMRN Sales Forecast

BMRN Stock Forecast FAQ

Detailed List of Analyst Forecasts